StockNews.AI
SYK
StockNews.AI
92 days

Stryker receives FDA clearance for OptaBlate® BVN Basivertebral Nerve Ablation System

1. Stryker's OptaBlate BVN received FDA clearance for treating chronic low back pain. 2. This system enhances Stryker's pain therapy portfolio with minimally invasive options. 3. OptaBlate BVN provides long-lasting pain relief, addressing an underserved patient population. 4. Stryker's Interventional Spine will present OptaBlate at ASPN Annual Meeting. 5. OptaBlate BVN can reduce the need for more invasive treatments like surgery.

7m saved
Insight
Article

FAQ

Why Bullish?

FDA clearance typically boosts stock prices, evidenced by similar approvals enhancing Stryker’s market performance.

How important is it?

The article indicates a significant advancement in Stryker's product line, potentially increasing revenue.

Why Short Term?

The immediate market response to FDA clearances often results in a short-term price increase.

Related Companies

MDTBSXABTIWKZBH
Stryker's first basivertebral nerve ablation system targets the basivertebral nerve to provide relief from chronic* vertebrogenic low back pain., /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced that its OptaBlate basivertebral nerve ablation system (OptaBlate BVN) received 510(k) clearance from the U.S. Food and Drug Administration. OptaBlate BVNA is used in a targeted minimally invasive procedure providing long-lasting† vertebrogenic pain relief1. The addition of the OptaBlate BVN to Stryker's pain portfolio expands its advanced pain therapy solutions for patients and is an intersection of its two core competencies: radiofrequency ablation technology and vertebral access. OptaBlate BVN ablation in vertebral body OptaBlate BVN – generator and probes "We often see patients with chronic low back pain who have tried multiple treatments—physical therapy, injections, medications—without lasting relief," said Dr. Jad Khalil, Spine Surgeon at Michigan Orthopaedic Surgeons. "BVNA is a minimally invasive and innovative procedure that targets a key source of this pain, particularly in patients with specific MRI findings. Before BVNA, options for lasting relief were limited. For many, it offers meaningful improvement and can help avoid more aggressive treatments like surgery." Key features of the system include: Achieves at least a 1 cm lesion in 7 minutes2 Steerable, dynamic curved introducer for targeted performance2 Microinfusion technology, which keeps the zone hydrated, reducing impedance errors and preventing charring2 10-gauge access tools "We have a long history in radiofrequency ablation, and we're relentlessly committed to delivering groundbreaking approaches to protect and promote quality of life," said Kristen Berg, vice president and general manager of Stryker's Interventional Spine business. "Our legacy providing solutions to reduce pain now continues with OptaBlate BVN, addressing the underserved population suffering from chronic vertebrogenic lumbar pain."Stryker's Interventional Spine business will introduce OptaBlate BVN as part of its pain portfolio at the American Society of Pain & Neuroscience (ASPN) Annual Meeting, July 17-20, in Miami, FL. (Booth #154).For questions, please click here.About StrykerStryker is a global leader in medical technologies and, together with its customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.Media contactBeth SizemoreSenior Director, Communications[email protected] *Chronic low back pain of at least six months duration that has not responded to at least six months of conservative care†The evidence shows patients treated with BVNA had sustained benefits in pain and function for up to 5 years References Fischgrund JS, Rhyne A, Macadaeg K, Moore G, Kamrava E, Yeung C, Truumees E, Schaufele M, Yuan P, DePalma M, Anderson DG, Buxton D, Reynolds J, Sikorsky M. Long-term outcomes following intraosseous basivertebral nerve ablation for the treatment of chronic low back pain: 5-year treatment arm results from a prospective randomized double-blind sham-controlled multi-center study. Eur Spine J. 2020 Aug;29(8):1925-1934. doi: 10.1007/s00586-020-06448-x. Epub 2020 May 25. PMID: 32451777. Stryker data on file. SOURCE Stryker WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News